NRx partner Emobot reports pooled clinical validation of EMOCARE depression monitoring tool at ASCP 2026

NRX Pharmaceuticals, Inc.

NRX Pharmaceuticals, Inc.

NRXP

0.00
  • NRx Pharmaceuticals flagged clinical validation results for Emobot Health’s EMOCARE depression monitoring tool, already presented at ASCP 2026.
  • Pooled observational studies in adults with major depressive disorder or bipolar disorder showed EMOCARE broadly tracked clinician assessments of depression.
  • Results also indicated the tool was responsive to changes in patient-reported symptoms across follow-up visits.
  • NRx plans deployment across the Hope Therapeutics psychiatry clinic network to support between-visit monitoring and relapse detection.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NRX Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605280700PRIMZONEFULLFEED9727930) on May 28, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.